Resultados da busca - Devi SenGupta

  • Mostrando 1 - 20 resultados de 20
Refinar Resultados
  1. 1
    Age but not disease progression defines CD4<sup>+</sup> and CD8<sup>+</sup> T stem cell memory levels in human retroviral infections: contrasting effects of HTLV-1 and HIV-1

    Age but not disease progression defines CD4<sup>+</sup> and CD8<sup>+</sup> T stem cell memory levels in human retroviral infections: contrasting effects of HTLV-1 and HIV-1 por Soraya Maria Menezes, Fábio E. Leal, Susan Pereira Ribeiro, Tim Dierckx, Mario Roederer, Devi SenGupta, Douglas F. Nixon, Johan Van Weyenbergh

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Pré-impressão
    Salvar na lista
    Na minha lista:
  2. 2
    Age-Related Expansion of Tim-3 Expressing T Cells in Vertically HIV-1 Infected Children

    Age-Related Expansion of Tim-3 Expressing T Cells in Vertically HIV-1 Infected Children por Ravi Tandon, Maria Teresa Maidana Giret, Devi SenGupta, Vanessa A. York, Andrew Wiznia, Michael Rosenberg, Esper G. Kallás, Lishomwa C. Ndhlovu, Douglas F. Nixon

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection

    Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection por Henri‐Alexandre Michaud, Miguel de Mulder Rougvie, Devi SenGupta, Steven G. Deeks, Jeffrey N. Martin, Christopher D. Pilcher, Frederick Hecht, Jonah B. Sacha, Douglas F. Nixon

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

    Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks por Rima Acosta, Madeleine Willkom, Ross Martin, Silvia Chang, Xuelian Wei, William Garner, Justin Lutz, Sophia R. Majeed, Devi SenGupta, Hal Martin, Erin Quirk, Kirsten L. White

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    The CD8 <sup>+</sup> Memory Stem T Cell (T <sub>SCM</sub> ) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection

    The CD8 <sup>+</sup> Memory Stem T Cell (T <sub>SCM</sub> ) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection por Susan Pereira Ribeiro, Jeffrey M. Milush, Edécio Cunha‐Neto, Esper G. Kallás, Jorge Kalil, Ma Somsouk, Peter W. Hunt, Steven G. Deeks, Douglas F. Nixon, Devi SenGupta

    Publicado em 2014
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection

    Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection por Dominic Paquin‐Proulx, Christina B. Ching, Ivan Vujkovic-Cvijin, Douglas Fadrosh, Liyen Loh, Yong Huang, Ma Somsouk, Susan V. Lynch, Peter W. Hunt, Douglas F. Nixon, Devi SenGupta

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    p16INK4a Expression and Immunologic Aging in Chronic HIV Infection

    p16INK4a Expression and Immunologic Aging in Chronic HIV Infection por Susan Pereira Ribeiro, Jeffrey M. Milush, Edécio Cunha‐Neto, Esper G. Kallás, Jorge Kalil, Luiz Felipe Domingues Passero, Peter W. Hunt, Steven G. Deeks, Douglas F. Nixon, Devi SenGupta

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II

    Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II por Devi SenGupta, Philip J. Norris, Todd J. Suscovich, Mina Hassan‐Zahraee, Howell Moffett, Alicja Trocha, Rika Draenert, Philip Goulder, Robert Binder, Daniel L. Levey, Bruce D. Walker, Pramod K. Srivastava, Christian Brander

    Publicado em 2004
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Switching to coformulated rilpivirine (<scp>RPV</scp>), emtricitabine (<scp>FTC</scp>) and tenofovir alafenamide from either <scp>RPV</scp>,<scp> FTC</scp> and tenofovir disoproxil fumarate (<scp>TDF</scp>) or efavirenz, <scp>FTC</scp> and <scp>TDF</scp>: 96‐week results from two randomized clinical trials

    Switching to coformulated rilpivirine (<scp>RPV</scp>), emtricitabine (<scp>FTC</scp>) and tenofovir alafenamide from either <scp>RPV</scp>,<scp> FTC</scp> and tenofovir disoproxil... por D Hagins, Chloe Orkin, ES Daar, Anthony Mills, Cynthia Brinson, E DeJesus, Frank A. Post, Javier O Morales‐Ramirez, Melanie Thompson, Olayemi Osiyemi, Bruce Rashbaum, H‐J Stellbrink, Claudia Martorell, H Liu, Y‐P Liu, Danielle Porter, S. E. Collins, Devi SenGupta, Manika Das

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

    Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment por Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, Mark Bloch, Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce

    Publicado em 2015
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    Multi-stakeholder consensus on a target product profile for an HIV cure

    Multi-stakeholder consensus on a target product profile for an HIV cure por Sharon R. Lewin, Timothy Attoye, Cathy Bansbach, Brian Doehle, Karine Dubé, Mark Dybul, Devi SenGupta, Adam Jiang, Rowena Johnston, Rosanne Lamplough, Joseph M. McCune, Gary J. Nabel, Thumbi Ndung’u, John C. Pottage, David H. Brown Ripin, James F. Rooney, Izukanji Sikazwe, Moses Supercharger Nsubuga, Mitchell Warren, Steven G. Deeks

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  12. 12
    Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate

    Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate por Samir K. Gupta, Frank A. Post, José Ramón Arribas, Joseph J. Eron, David A. Wohl, Amanda E. Clarke, Paul E. Sax, Hans‐Jürgen Stellbrink, Stefan Eßer, Anton Pozniak, Daniel Podzamczer, Laura Waters, Chloe Orkin, Jürgen K. Rockstroh, Tatiana Mudrikova, Eugènia Negredo, Richard Elion, Susan Guo, Lijie Zhong, Christoph C Carter, Hal Martin, Diana M. Brainard, Devi SenGupta, Moupali Das

    Publicado em 2019
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

    Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1 por Sharon A. Riddler, Michael F. Para, Constance A. Benson, Anthony Mills, Moti Ramgopal, Edwin DeJesus, Cynthia Brinson, Joshua C. Cyktor, Jana L. Jacobs, Dianna Koontz, John W. Mellors, Gregory M. Laird, Terri Wrin, Heena Patel, Susan Guo, Jeffrey J. Wallin, Jillian Boice, Liao Zhang, Rita Humeniuk, Rebecca Begley, Polina German, Hiba Graham, Romas Geleziunas, Diana M. Brainard, Devi SenGupta

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities

    Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities por Nicole Frahm, Bette Korber, Craig Adams, James Szinger, Rika Draenert, Marylyn M. Addo, Margaret E. Feeney, Karina Yusim, Kaori Sango, Nancy V. Brown, Devi SenGupta, Alicja Piechocka‐Trocha, Toni B. Simonis, Franco Marincola, Alysse G. Wurcel, David R. Stone, Christopher J. Russell, P. Adolf, Dani Cohen, Timothy Roach, A. StJohn, Ashok Khatri, Katie L. Davis, James I. Mullins, Philip Goulder, Bruce D. Walker, Christian Brander

    Publicado em 2004
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

    Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 por Jason D. Goldman, David Chien Lye, David S.C. Hui, Kristen Marks, Raffaele Bruno, Rocío Montejano, Christoph D. Spinner, Massimo Galli, Mi-Young Ahn, Ronald Nahass, Yao-Shen Chen, Devi SenGupta, Robert H. Hyland, Anu Osinusi, Huyen Cao, Christiana Blair, Xuelian Wei, Anuj Gaggar, Diana M. Brainard, William Towner, José Muñóz, Kathleen M. Mullane, Francisco M. Marty, Karen T. Tashima, George Diaz, Aruna Subramanian

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies

    Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective... por Jesper Damsgaard Gunst, Jesal Gohil, Jonathan Z. Li, Ronald J. Bosch, Caitlin White, Tae‐Wook Chun, Beatriz Mothe, Kathleen Gittens, Lauren Praiss, Marie‐Angélique De Scheerder, Linos Vandekerckhove, Kevin Escandón-Vargas, Ann Thorkelson, Timothy W. Schacker, Devi SenGupta, Christian Brander, Emmanouil Papasavvas, Luis J. Montaner, Javier Martínez‐Picado, Ruxandra Câlin, Antonella Castagna, Camilla Muccini, Wesley de Jong, Lorna Leal, Felipe García, Rob A. Gruters, Timothy Tipoe, John Frater, Ole S. Søgaard, Sarah Fidler

    Publicado em 2025
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  17. 17
    Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

    Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 por Christoph D. Spinner, Robert Gottlieb, Gerard J. Criner, José Ramón Arribas, Anna Maria Cattelan, Àlex Soriano, Onyema Ogbuagu, Prashant Malhotra, Kathleen M. Mullane, Antonella Castagna, Louis Yi Ann Chai, Meta Roestenberg, Owen Tak Yin Tsang, Enos Bernasconi, Paul Le Turnier, Shan‐Chwen Chang, Devi SenGupta, Robert H. Hyland, Anu Osinusi, Huyen Cao, Christiana Blair, Hongyuan Wang, Anuj Gaggar, Diana M. Brainard, Mark McPhail, Sanjay Bhagani, Mi Young Ahn, Arun J. Sanyal, Gregory Huhn, Francisco M. Marty

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial

    Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial por Lucía Bailón, Anuska Llano, Samandhy Cedeño, Tuixent Escribà, Míriam Rosás-Umbert, Mariona Parera, María Casadellà, Miriam Cebey‐López, Francisco Pérez, Bruna Oriol-Tordera, Marta Ruiz‐Riol, J Coll, Félix Pérez-Tejera, Àngel Rivero, Anne R. Leselbaum, Ian McGowan, Devi SenGupta, Edmund G. Wee, Tomáš Hanke, Roger Paredes, Yovaninna Alarcón‐Soto, Bonaventura Clotet, Marc Noguera-Julián, Christian Brander, José Moltó, Beatriz Mothe, Ana María Barriocanal, Susana Benet, Patricia Cobarsí, Romas Geleziunas, Anne R. Leselbaum, Cora Loste, Michael Meulbroek, Cristina Miranda, José F. Muñoz, Jordi Naval, Aroa Nieto, Ferran Pujol, Jordi Puig

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

    Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 por Steven G. Deeks, Nancie M. Archin, Paula M. Cannon, Simon Collins, R. Brad Jones, Marein A.W.P. de Jong, Olivier Lambotte, Rosanne Lamplough, Thumbi Ndung’u, Jeremy Sugarman, Caroline T. Tiemessen, Linos Vandekerckhove, Sharon R. Lewin, Steven G. Deeks, Sharon R. Lewin, Marein de Jong, Zaza M. Ndhlovu, Nicolas Chomont, Zabrina L. Brumme, Kai Deng, Luke D. Jasenosky, Richard Jefferys, Aurelio Orta‐Resendiz, Frank Mardarelli, Monique Nijhuis, Katharine J. Bar, Bonnie J. Howell, Alex Schneider, Gabriela Turk, Rose Nabatanzi, Joel N. Blankson, J. Víctor García, Mirko Paiardini, Jan van Lunzen, Christina Antoniadi, Fernanda Heloise Côrtes, Susana Valente, Ole S. Søgaard, Ricardo Sobhie Diaz, Melannie Ott, Richard M. Dunham, Siegfried Schwarze, Santiago Perez Patrigeon, Josephine Nabukenya, Marina Caskey, Beatriz Mothe, Fu Sheng Wang, Sarah Fidler, Devi SenGupta, Stephan Dressler, Mitch Matoga, Hans‐Peter Kiem, Pablo Tebas, Cissy Kityo, Boro Dropulić, Michael Louella, Kumitaa Theva Das, Deborah Persaud, Ann Chahroudi, Katherine Luzuriaga, Thanyawee Puthanakit, Jeffrey T. Safrit, Gaerolwe Masheto, Karine Dubé, Jennifer Power, Jessica Salzwedel, Udom Likhitwonnawut, Jeff Taylor, Oguzhan Latif Nuh, Krista L. Dong, Edward Nelson Kankaka

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  20. 20
    Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

    Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial por Lucía Bailón, José Moltó, Adrián Curran, Julen Cadiñanos, Juan Carlos López Bernaldo de Quirós, Ignacio de los Santos, Juan Ambrosioni, Arkaitz Imaz, Susana Benet, Paula Suanzes, Jordi Navarro, Juan González, Carmen Busca, Leire Pérez‐Latorre, Juan Berenguer, Lucio García‐Fraile, Gina Mejía‐Abril, José M Miró, Sofía Scévola, Santiago Moreno, Peré Domingo, Yuan Tian, Michelle Frankot, Daina Lim, Yanhui Cai, Elena Vendrame, Susan Guo, Jeffrey J. Wallin, Romas Geleziunas, Devi SenGupta, Yovaninna Alarcón‐Soto, Isabel Leal, Alvaro Aranguen, María Luz García‐García, Ian McGowan, Christian Brander, José Ramón Arribas, Beatriz Mothe, Ignacio de los Santos, Patricia Cobarsí, Cristina Martínez, Aroa Nieto, Francisco A. Perez, Jordi Puig, Samandhy Cedeño, Bonaventura Clotet, Eulàlia Grau, Anuska Llano, Roger Paredes, J. Cabero, Jordi Naval, Vicenç Falcó, Bibiana Planas, Joaquín Burgos, María J. Buzón, Meritxell Genescà, Judith Grau-Expósito, Alberto M. Borobia, Víctor Hontañón, Javier Queiruga, Rafael Micán, Enrique Seco, Cristina Díez, Paloma Gijón, Margarita Ramírez, Samuel Martín‐Vílchez, Alejandro de Miguel‐Cáceres, J. M. Serra, Tamara De la Torre-Muñoz, Eva Ariza, Anna Ferrer, Benito García, Sandra Morenilla, Jordí Niubó, Camila Piatti, Irene Soriano, Daniel Vázquez

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: